Key Highlights
● Cash and securities were $201.1 million at 30 June 2026, up from $125.7 million.
● A $100 million offering included a $40 million strategic investment by Eli Lilly.
● Net loss widened to $33.2 million from $30.6 million a year earlier.
● ABS-201 interim data showed an estimated half-life of at least 65 days.
Absci Corporation (NASDAQ:ABSI), a biotechnology company, reported second-quarter 2026 results on 11 August 2026 that combined a larger loss with a markedly stronger balance sheet. The common stock trades on the Nasdaq under ABSI. The results release was filed with the US Securities and Exchange Commission as an exhibit to a Form 8-K.
Historical results
For the three months ended 30 June 2026, Absci reported revenue of $318 thousand, down from $593 thousand a year earlier. The net loss widened to $33.2 million from $30.6 million in the second quarter of 2025. Net loss per share was $0.21, compared with $0.24 previously, which reflects a larger share count after the equity raise.
Cash, cash equivalents and marketable securities stood at $201.1 million at 30 June 2026, against $125.7 million at 31 March 2026. The increase includes $93.6 million of net proceeds from a $100 million underwritten offering, which featured a $40 million strategic equity investment by Eli Lilly and Company. The company said that Lilly's involvement does not grant it rights to any Absci programme, and a Lilly representative has joined the company's Endometriosis Advisory Board.
Management guidance and the pipeline
Management said that its cash, cash equivalents and marketable securities should fund operations into the second half of 2028. That is a company expectation, not a guarantee, and it depends on spending, trial outcomes and the capital markets.
The lead asset is ABS-201, an antibody being developed for pattern hair loss and endometriosis. In the HEADLINE Phase 1 trial, Absci reported positive interim data for hair loss. The drug appeared well tolerated across the blinded single ascending dose cohorts, and the estimated half-life was at least 65 days. The company said this could support dosing two or three times over six months, pending further follow-up. Dosing in the multiple ascending dose portion continues.
A second candidate, ABS-202, is an anti-PRLR antibody in preclinical development for an undisclosed immunology and inflammation indication.
Why it matters
Biotechnology companies with little revenue depend on external funding to reach clinical data. Absci's revenue is small relative to its loss, so the cash position and runway are central to its risk profile. The strategic investment from a large pharmaceutical group conveyed no programme rights, according to the company.
Disclosed milestones
The company listed the following expected events:
Interim proof-of-concept data for ABS-201 in pattern hair loss in the second half of 2026; initiation of a Phase 2 trial in endometriosis in the fourth quarter of 2026; full 26-week proof-of-concept data in hair loss in early 2027; and proof-of-concept data in endometriosis in the second half of 2027.
As of 13 October 2026, the second-half 2026 hair loss readout and the Phase 2 start are the nearest items, and the release gives no exact dates for either of them.
Early-Stage Risk, Modest Revenue and Dilution Effects
Early-stage antibody programmes carry high failure rates, and interim data from a small Phase 1 study cannot establish efficacy. Revenue is modest and may vary with partnership timing. Offering dilution also affects per-share comparisons across periods. The figures are reported quarterly results from the company's own release, and the guidance is management's own.






Please wait processing your request...